fda warning about semaglutide The sent a letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know black box warning for semaglutide

Vascular mimicry Aggressively growing tumor cells can form vessel like structures through a process denoted as vascular mimicry

Practical considerations for researchers Beyond the clinical data, practical factors influence which compound works better in real-world research settings

Although compounded formulations helped fill access gaps during the national GLP-1 shortage, these products remain unapproved and subject to strict regulatory limits

BPI Labs is launching a number of 503B injectable products, the lawsuit warned, claiming the facility was built to produce large batches with or without prescriptions. The case settled on May 21, according to PACER

The full research findings are available online